Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-13
2007-02-13
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100, C530S300000, C530S330000, C530S350000
Reexamination Certificate
active
10252978
ABSTRACT:
A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4833092 (1989-05-01), Gevsen
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5591719 (1997-01-01), Furcht et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 0 314 863 (1989-05-01), None
patent: 0 330 506 (1989-09-01), None
patent: 0 333 517 (1989-09-01), None
patent: 0 346 078 (1989-12-01), None
patent: WO 90/03400 (1990-04-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/03252 (1991-03-01), None
patent: WO 92/00751 (1992-01-01), None
patent: WO 92/14757 (1992-09-01), None
patent: WO 93/15764 (1993-08-01), None
patent: WO 95/19790 (1995-07-01), None
Albelda et al., FASEB Journal 8: 504-512, 1994.
Brown, Jr., P. et al., “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival”,Proc. Natl. Acad. Sci. USA,88:2663-2667 (1990).
Burkly, L. et al., “Signalling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation”,Eur. J. Immunol.,21:2871-2875 (1991).
Clackson, T. et al., “Making Antibody Fragments Using Phage Display Libraries”,Nature,352:624-628 (1991).
Co, M.S. et al., “Humanized Antibodies for Antiviral Therapy”,Proc. Natl. Acad. Sci. USA,88:2869-2873 (1990).
Damle, N. et al., “Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4+Lymphocytes”,Proc. Natl. Acad. Sci. USA,88:6403-6407 (1991).
Devlin, J. et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”,Science,249:400-406 (1990).
Dobrina, A. et al., “Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells”,J. Clin. Invest.,88:20-26 (1991).
Edgington, Biotechnology 10: 383-389, 1992.
Elices, M.J. et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site”,Cell,60:577-584 (1990).
Freedman, A. et al., “Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110”,Science,249:1030-1033 (1990).
Harris, W.J. and S. Emery, “Therapeutic antibodies—the coming of age”,TIBTECH,11:42-44 (1993).
Hemler, M.E. et al., “Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides”,J. Biol. Chem.,262(24):11478-11485 (1987).
Holzmann, B. and I.L. Weissman, “Integrin Molecules Involved in Lymphocyte Homing to Peyer's Patches”,Immunolical Reviews,0(108):45-61 (1989).
Holzmann, B. et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α”,Cell,56:37-46 (1989).
Issekutz, T., “Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody”,J. Immunol.,147:4178-4184 (1991).
Jakubowski et al., “Vascular Cell Adhesion Molecule (VCAM)-1g Fusion Protein Defines Distinct Affinity States of the Very Late Antigen-4 (VLA-4) Receptor”,Cell Adhesion and Communications,3:131-142 (1995).
Jones et al., Gut 36: 724-730, 1995.
Jones, P.T. et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse”,Nature,321:522-525 (1986).
Jutila, M.A. et al., “Homing Receptors in Lymphocyte, Neutrophil, and Monocyte Interaction with Endothelial Cells” inLeukocyte Adhesion Molecules,T.A. Springer et al. (eds) (New York: Springer-Verlag New York Inc., 1990) Chp. 17, 227-235.
Kilshaw, P. and S.J. Murant, “Expression and Regulation of β7(βp) Integrins on Mouse Lymphocytes: Relevance to the Mucosal Immune System”,Eur. J. Immunol.,21:2591-2597 (1991).
KÖhler, G. and C. Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”,Nature,265:495-497 (1975).
Koizumi, M. et al., “Expression of Vascular Adhesion Molecules in Inflammatory Bowel Disease”,Gastroent.,103:840-847 (1992).
Lichtiger, S. and D.H. Present, “Preliminary Report: Cyclosporin in Treatment of Severe Active Ulcerative Colitis”,Lancet,336:16-19 (1990).
Lobb, R. et al., “Expression and Functional Characterization of a Soluble Form of Vascular Cell Adhesion Molecule 1”,Biochem. Biophys. Res. Commun.,178(3):1498-1504 (1991).
Lobb, R. et al., “Expression and Functional Characterization of a Soluble Form of Endothelial-Leukocyte Adhesion Molecule”,J. Immunol.,147(1):124-129 (1991).
Lobb, R. et al., “Vascular Cell Adhesion Molecule-1”, inCellular and Molecular Mechanisms of Inflammation: Vascular Adhesion Molecules,vol. 2, C.G. Cochrane and M.A. Gimbrone, Jr. (eds.) (New York: Academic Press Inc., 1991) Chp. 8, 151-169.
Madara, J. et al., “Characterization of Spontaneous Colitis in Cotton-Top Tamarin (Saguinus oedipus) and Its Response to Sulfasalazine”,Gastroent.,88:13-19 (1985).
Malizia, G. et al., “Expression of Leukocyte Adhesion Molecules by Mucosal Mononuclear Phagocytes in Inflammatory Bowel Disease”,Gastroent.,100:150-159 (1991).
Osband, M.E. and S. Ross, “Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy”,Immunol. Today,11:193-195 (1990).
Osborn, L., “Leukocyte Adhesion to Endothelium in Inflammation”,Cell,62:3-6 (1990).
Osborn, L. et al., “Direct Expression Cloning of Vascular Cell Adhesion Molecule I, a Cytokine-induced Endothelial Protein That Binds to Lymphocytes”,Cell,59:1203-1211 (1989).
Podolsky, D.K., “Colonic Glycoproteins in Ulcerative Colitis: Potentials Meaning in Heterogeneity”,Inflammatory Bowel Diseases: Basic Research and Clinical Implications,Falk Symposium, Titisee, Germany, Jun. 7-9, 1987 (Boston, MA: Kluwer Academic Publishers, 1987) pp. 49-56.
Podolsky, D.K. and D.A. Fournier, “Alterations in Mucosal Content of Colonic Glycoconjugates in Inflammatory Bowel Disease Defined by Monoclonal Antibodies”,Gastroent.,95:379-387 (1988).
Podolsky, D.K. and D.A. Fournier, “Emergence of Antigenic Glycoprotein Structures in Ulcerative Colitis Detected Through Monoclonal Antibodies”,Gastroent.,95:371-378 (1988).
Podolsky, D.K. et al., “Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 Integrin Monoclonal Antibody”,J. Clin. Invest.,92:372-380 (1993).
Podolsky, D.K. et al., “Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin”,Gastroent.,88:20-25 (1985).
Podolsky, D.K. et al., “Spontaneous Colitis in Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chromic Colitis”,Digestive Diseases and Sciences,30(4):396 (A-32) (1985).
Pulido, R. et al., “Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4”,J. Biol. Chem.,266(16):10241-10245 (1991).
Rice, G.E. et al., “Vascular and Nonvascular Expression of INCAM-110”,Am. J. Pathology,138(2):385-393 (1991).
Riechmann, L. et al., “Reshaping Human Antibodies for Therapy”,Nature,332:323-327 (1988).
Salmi, M. and S. Jalkanen, “Regulation of Lymphocyte Traffic to Mucosa-Associated Lymphatic Tissues”Gastroent. Clin. N. Am.,20(3):495-510 (1991).
Sanchez-Madrid, F. et al., “VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution a
Burkly Linda C.
Lobb Roy R.
Biogen Idec MA Inc.
Fish & Richardson P.C.
Gambel Phillip
LandOfFree
Treatment for inflammatory bowel disease with a fibronectin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for inflammatory bowel disease with a fibronectin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for inflammatory bowel disease with a fibronectin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3884117